Essential Polyunsaturated Fatty Acids in Blood from Patients with and without Catheter-Proven Coronary Artery Disease.
Chaoxuan WangJörg EnssleAnne PietznerChristoph SchmöckerLinda WeilandOliver RitterMonique JaenschUlf ElbeltNikolaos PagonasKarsten-Henrich WeylandtPublished in: International journal of molecular sciences (2022)
Coronary artery disease (CAD) is the leading cause of death worldwide. Statins reduce morbidity and mortality of CAD. Intake of n-3 polyunsaturated fatty acid (n-3 PUFAs), particularly eicosapentaenoic acid (EPA), is associated with reduced morbidity and mortality in patients with CAD. Previous data indicate that a higher conversion of precursor fatty acids (FAs) to arachidonic acid (AA) is associated with increased CAD prevalence. Our study explored the FA composition in blood to assess n-3 PUFA levels from patients with and without CAD. We analyzed blood samples from 273 patients undergoing cardiac catheterization. Patients were stratified according to clinically relevant CAD ( n = 192) and those without ( n = 81). FA analysis in full blood was performed by gas chromatography. Indicating increased formation of AA from precursors, the ratio of dihomo-gamma-linolenic acid (DGLA) to AA, the delta-5 desaturase index (D5D index) was higher in CAD patients. CAD patients had significantly lower levels of omega-6 polyunsaturated FAs (n-6 PUFA) and n-3 PUFA, particularly EPA, in the blood. Thus, our study supports a role of increased EPA levels for cardioprotection.
Keyphrases
- coronary artery disease
- fatty acid
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- percutaneous coronary intervention
- cardiovascular events
- coronary artery bypass grafting
- prognostic factors
- peritoneal dialysis
- type diabetes
- cardiovascular disease
- patient reported outcomes
- mass spectrometry
- atrial fibrillation
- body mass index
- acute coronary syndrome
- big data
- weight loss
- high resolution mass spectrometry